Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Biomarkers of Clinical Resistance to Decitabine and Venetoclax Therapy Inferred By Transcriptome and Methylation Analyses

Kotoko Yamatani, Abhishek Maiti, Tatsuro Watanabe, Kaori Saito, Kala Hayes, Sonoko Kinjo, Kazuho Ikeo, Takashi Miida, Shinya Kimura, Courtney D. DiNardo, Xiaoping Su, Yoko Tabe, Marina Konopleva

Blood (2022) 140 (Supplement 1): 3097–3098.

https://doi.org/10.1182/blood-2022-156999

Published: 2022

Journal Articles

Diverse Mechanisms of Resistance to Decitabine and Venetoclax Therapy in Newly Diagnosed and Relapsed/Refractory AML Inferred By Transcriptome Analysis

Kotoko Yamatani, Yoko Tabe, Abhishek Maiti, Tomohiko Ai, Kaori Saito, Kazuhiro R Nitta, Sonoko Kinjo, Kazuho Ikeo, Takashi Miida, Courtney D. DiNardo, Xiaoping Su, Marina Konopleva

Blood (2021) 138 (Supplement 1): 2244.

https://doi.org/10.1182/blood-2021-149432

Published: 2021

Journal Articles

BCL2A1 : A Novel Target in Refractory Acute Myeloid Leukemia with FLT3 -ITD/D835 Dual Mutations

Kotoko Yamatani, MD, Tomohiko Ai, MDPhD, Kaori Saito, Haeun Yang, Vivian Ruvolo, MS, Po Yee Mak, Sonoko Kinjo, PhD, Kazuho Ikeo, PhD, Hironori Harada, MD PhD, Kazuhiro Katayama, PhD, Takashi Miida, MD PhD, Marina Konopleva, MD PhD, Weiguo Zhang, MD PhD, Bing Z Carter, PhD, Yoshihide Hayashizaki, MD PhD, Michael Andreeff, MD PhD, Yoko Tabe, MD PhD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-136587

Published: 2020

Journal Articles

Cage Transcriptome Analysis Reveals BCL2A1 Upregulation in FLT3 -ITD/D835 Dual Mutated AML Cells Harboring Complex Co-Mutations

Kotoko Yamatani, MD, Tomohiko Ai, MD PhD, Kaori Saito, Haeun Yang, Koya Suzuki, PhD, Atsushi Hori, PhD, Yuko Murakami-Tonami, MD PhD, Weiguo Zhang, MD PhD, Bing Z Carter, PhD, Sonoko Kinjo, PhD, Kazuho Ikeo, PhD, Katayama Kazuhiro, Hironori Harada, MD PhD, Takashi Miida, MD PhD, Neil P. Shah, MD PhD, Marina Y Konopleva, MD PhD, Yoshihide Hayashizaki, MD PhD, Michael Andreeff, MD PhD, Yoko Tabe, MD PhD

Blood (2019) 134 (Supplement_1): 1264.

https://doi.org/10.1182/blood-2019-124685

Published: 2019

Journal Articles

Upregulation of Bcl-2 Confers Resistance to FLT3 Inhibition in FLT3 -ITD AML with Secondary Acquired Mutations

Kotoko Yamatani, MD, Yoko Tabe, MD PhD, Kaori Saito, Haeun Yang, Yuko Murakami-Tonami, MD PhD, Koya Suzuki, PhD, Weiguo Zhang, MD PhD, Sonoko Kinjo, PhD, Kazuho Ikeo, PhD, Kaoru Mogushi, PhD, Masaki Hosoya, PhD, Shigeo Yamaguchi, MD PhD, Hironori Harada, MD PhD, Takashi Miida, MD PhD, Neil P. Shah, MD PhD, Marina Y. Konopleva, MD PhD, Yoshihide Hayashizaki, MD PhD, Michael Andreeff, MD PhD

Blood (2018) 132 (Supplement 1): 3944.

https://doi.org/10.1182/blood-2018-99-109957

Published: 2018

Journal Articles

Combined Targeting of Bcl-2 and XPO1 Overcomes Acquired Resistance to Tyrosine Kinase Inhibitors in the FLT3-ITD/TKD Double Mutant AML

Yoko Tabe, MD PhD, Kotoko Yamatani, MD, Haeun Yang, Kaori Saito, Yuko Murakami-Tonami, MD, Koya Suzuki, PhD, Weiguo Zhang, MD PhD, Sonoko Kinjo, PhD, Kazuho Ikeo, PhD, Masaki Hosoya, PhD, Kaoru Mogushi, PhD, Shigeo Yamaguchi, Hironori Harada, MD PhD, Takashi Miida, MD PhD, Neil Shah, MD, Marina Y. Konopleva, MD PhD, Yoshihide Hayashizaki, MD PhD, Michael Andreeff, MD PhD

Blood (2018) 132 (Supplement 1): 2640.

https://doi.org/10.1182/blood-2018-99-113195

Published: 2018

Journal Articles

XPO1 Inhibition Targets Transcriptional Vulnerability of FLT3-ITD+D835 Double Mutant AML through p53 Accumulation and Inhibition of Oncogenic Transcription Factors: Lesson Learned from Cage Sequencing of Primary AML Cells

Kotoko Yamatani, MD PhD, Yoko Tabe, MD PhD, Kazumasa Sekihara, PhD, Haeun Yang, Kaori Saito, Weiguo Zhang, MD PhD, Kazuho Ikeo, PhD, Sonoko Kinjo, Kaoru Mogushi, PhD, Masaki Hosoya, Yoshihide Hayashizaki, MD PhD, Yasunari Yamanaka, MD PhD, Hironori Harada, Takashi Miida, MD PhD, Marina Konopleva, MD PhD, Michael Andreeff, MD PhD

Blood (2017) 130 (Supplement 1): 1244.

https://doi.org/10.1182/blood.V130.Suppl_1.1244.1244

Published: 2017

NARROW

Biomarkers of Clinical Resistance to Decitabine and Venetoclax Therapy Inferred By Transcriptome and Methylation Analyses

Diverse Mechanisms of Resistance to Decitabine and Venetoclax Therapy in Newly Diagnosed and Relapsed/Refractory AML Inferred By Transcriptome Analysis

BCL2A1 : A Novel Target in Refractory Acute Myeloid Leukemia with FLT3 -ITD/D835 Dual Mutations

Cage Transcriptome Analysis Reveals BCL2A1 Upregulation in FLT3 -ITD/D835 Dual Mutated AML Cells Harboring Complex Co-Mutations

Upregulation of Bcl-2 Confers Resistance to FLT3 Inhibition in FLT3 -ITD AML with Secondary Acquired Mutations

Combined Targeting of Bcl-2 and XPO1 Overcomes Acquired Resistance to Tyrosine Kinase Inhibitors in the FLT3-ITD/TKD Double Mutant AML

XPO1 Inhibition Targets Transcriptional Vulnerability of FLT3-ITD+D835 Double Mutant AML through p53 Accumulation and Inhibition of Oncogenic Transcription Factors: Lesson Learned from Cage Sequencing of Primary AML Cells

Email alerts

ASH Publications

American Society of Hematology

Biomarkers of Clinical Resistance to Decitabine and Venetoclax Therapy Inferred By Transcriptome and Methylation Analyses

Diverse Mechanisms of Resistance to Decitabine and Venetoclax Therapy in Newly Diagnosed and Relapsed/Refractory AML Inferred By Transcriptome Analysis

BCL2A1 : A Novel Target in Refractory Acute Myeloid Leukemia with FLT3 -ITD/D835 Dual Mutations

Cage Transcriptome Analysis Reveals BCL2A1 Upregulation in FLT3 -ITD/D835 Dual Mutated AML Cells Harboring Complex Co-Mutations

Upregulation of Bcl-2 Confers Resistance to FLT3 Inhibition in FLT3 -ITD AML with Secondary Acquired Mutations

Combined Targeting of Bcl-2 and XPO1 Overcomes Acquired Resistance to Tyrosine Kinase Inhibitors in the FLT3-ITD/TKD Double Mutant AML

XPO1 Inhibition Targets Transcriptional Vulnerability of FLT3-ITD+D835 Double Mutant AML through p53 Accumulation and Inhibition of Oncogenic Transcription Factors: Lesson Learned from Cage Sequencing of Primary AML Cells

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only